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This article examines rates of nonmedical use and diversion of extended-release amphetamine
and extended-release oral methylphenidate in the United States. Prescription dispensing
data were sourced from retail pharmacies. Nonmedical use data were collected from the
Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Drug
Diversion Program and Poison Center Program. Drug diversion trends nearly overlapped
for extended-release amphetamine and extended-release oral methylphenidate. Calls to poi-
son centers were generally similar; however, calls regarding extended-release amphetamine
trended slightly lower than those for extended-release oral methylphenidate. Data suggest sim-
ilar diversion and poison center call rates for extended-release amphetamine and extended-
release oral methylphenidate.
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BACKGROUND
Prescription stimulants have been recom-
mended as first-line medications in the phar-
macologic treatment of attention-deficit hyper-
activity disorder (ADHD).1 These medications
include methylphenidate and amphetamine
and they are available in traditional immediate-
release formulations and in modified- or
extended-release formulations (oral tablets and
capsules, a methylphenidate transdermal patch,
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and an amphetamine prodrug), which allow for
less frequent dosing. With all of these medica-
tions, the potential exists for nonmedical use
(the use of prescription medications in a man-
ner inconsistent with the prescribed indication
and dosing), and ADHD stimulants are classi-
fied as Schedule II controlled substances in the
United States based on their potential for abuse,
dependence, and individual and public health
harm, which is consistent with the Convention
on Psychotropic Substances 1971.2
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In this article, we focus on post-marketing
surveillance in the United States for rates of
abuse, misuse, and diversion of ADHD med-
ications because extensive data are available.
Time trends of abuse, misuse, and diversion of
extended-release amphetamine and extended-
release oral methylphenidate are compared
because these products are commonly pre-
scribed in the United States and because of
interest in extended-release formulations as
a possible mechanism to improve adherence
among patients. Data are presented from the
Researched Abuse, Diversion and Addiction-
Related Surveillance (RADARS) System, a na-
tional surveillance system that monitors the
abuse, misuse, and diversion of prescrip-
tion controlled substances (e.g., pharmaceuti-
cal medicines with psychoactive properties).3
We are not aware of any published studies us-
ing national data sources that measure rates of
nonmedical use of stimulants by formulation in
the post-marketing setting.
METHODS
For the purposes of this article, diversion is de-
fined as the unlawful channeling of regulated
pharmaceuticals from legal sources to the illicit
marketplace.4 Use is defined as any use of the
drug, with no restrictions as to purpose or legal-
ity. Nonmedical use includes both abuse and
misuse. Abuse is defined as the intentional im-
proper or incorrect use of a drug for the pur-
poses of experiencing psychotropic effects (e.g.,
to get high) that may cause harm to the user
or others; conversely, misuse is the intentional
improper or incorrect use of a substance for
reasons other than to get high (such as taking
an additional dose without consulting with a
prescriber because an individual believes that
his or her symptoms were not adequately con-
trolled).5 The reporting period of quarter 3 of
2007 through quarter 2 of 2011 was chosen
because RADARS first began collecting infor-
mation on prescription stimulants in quarter 3
of 2007 and the most recent data available at
the time of this study was from quarter 2 of
2011.
Stimulant Prescribing
The IMS Health National Prescription Audit
(NPA) is a standard data commercial source that
measures the retail outflow, or retail outpatient
dispensing, of prescriptions in the United States,
which represents the rate at which drugs move
out of independent, chain, and food store retail
pharmacies into the hands of consumers. Ac-
cording to estimates by IMS Health,6 approxi-
mately 55% of all prescriptions dispensed in the
United States (including Alaska and Hawaii) are
accounted for by independent, chain, and food
store retail pharmacies.
The NPA sample is updated on a monthly
basis and consists of approximately 36,000
to 38,000 randomly selected stores. In 2011,
the sample consisted of 38,326 retail phar-
macies, including 22,526 chain pharmacy
stores, 8,206 independent pharmacy stores,
and 7,594 food store pharmacies. This sample
was drawn from 56,996 pharmacies (29,528
chain pharmacies, 17,701 independent phar-
macies, and 9,767 food store pharmacies).
The estimated number of dispensed prescrip-
tions was projected nationally from this sam-
ple using proprietary methods linked to a
unique patient identifier. From July 1, 2007,
through June 30, 2011, the total number of
U.S. prescriptions dispensed for all prescrip-
tion extended-release amphetamine products
and all extended-release oral methylphenidate
products (Table 1) were calculated by quarter.
TABLE 1. Extended-Release Amphetamine and Oral Methyl-
phenidate Prescription Products in IMS NPA
Extended-release Extended-release oral
amphetamine† methylphenidate†






Metadate CD (UCB Inc.)





† The listed products are United States trade names and may
not be available in other countries. Formulations vary among
products.
28 M. A. SEMBOWER ET AL.
Measurement of Abuse, Misuse,
and Diversion of Prescription Stimulants
The RADARS System is a national surveillance
system that monitors the abuse, misuse, and
diversion of prescription pharmaceutical prod-
ucts. In this article, data are used from the
RADARS System Drug Diversion and Poison
Center Programs. The other RADARS System
programs focus their data collection on opioids
and were unable to collect data on prescrip-
tion stimulants.3 The RADARS System collects
and reports data on a quarterly basis with geo-
graphic specificity at the 3-digit ZIP code (U.S.
postal code) level throughout the United States.
There are 929 3-digit ZIP codes in the United
States. Data used in this analysis were obtained
from quarter 3 of 2007 through quarter 2 of
2011.
The RADARS System Drug Diversion Pro-
gram is composed of prescription drug diver-
sion investigators or state regulatory agencies
that submit data quarterly and report the num-
ber of new diversion cases investigated in that
quarter. In 2007, there was a quarterly aver-
age of 244 reporting investigators or agencies
out of 301 participating investigators or agen-
cies (covering an average of 486 3-digit ZIP
codes per quarter), 250 of 308 in 2008 (554
3-digit ZIP codes), 256 of 299 in 2009 (511
3-digit ZIP), and 242 of 283 in 2010 (487 3-digit
ZIP codes). In quarter 1 and 2 of 2011, there
were 229 of 264 (458 3-digit ZIP codes) and
220 of 264 (458 3-digit ZIP codes) reporting
investigators or agencies, respectively. Variabil-
ity in represented 3-digit ZIP codes over time
is a result of reporter jurisdiction changes and
consistency of survey submissions. Cases are de-
fined as the number of new instances of phar-
maceutical diversion reported to or investigated
by the diversion unit or regulatory board during
the previous quarter. Cases must be formally
initiated during the quarter and documented
by a written complaint or report. Cases are as-
signed to the 3-digit ZIP code where the case
occurred or, when the 3-digit ZIP code where
the case occurred is not specified, cases are dis-
tributed across the 3-digit ZIP codes in the infor-
mant’s jurisdiction. The reporters are requested
to give as much detail as possible on the for-
mulations and brands of the products involved
in the cases. More detailed descriptions of the
Drug Diversion Program have been published
previously.3,4,7
The RADARS System Poison Center Pro-
gram is composed of participating U.S. poi-
son centers, which choose to participate in
the RADARS System. These poison centers
send data on cases involving RADARS System
drugs of interest on a weekly basis to a central
database maintained by the RADARS System.
For 2007, an average of 43 poison centers par-
ticipated per quarter, with 40 of those poison
centers reporting per quarter (covering an aver-
age of 675 3-digit ZIP codes per quarter), 45 of
46 in 2008 (736 3-digit ZIP codes), 48 of 48 in
2009 (788 3-digit zip codes), and 49 of 49 in
2010 (789 3-digit ZIP codes); in quarter 1 and
2 of 2011, 47 of 47 poison centers (788 3-digit
ZIP codes) reported. Spontaneous reports from
the public, health care professionals, and other
public safety professionals received by poison
centers (for which the sampling frame is un-
specified) are answered by nurses and pharma-
cists who have training in clinical toxicology and
have passed a national certification examina-
tion.8 Each case is recorded in nationally stan-
dardized electronic health records and subject
to quality control processes to verify the identity
of the drugs involved and ensure coding accu-
racy. For the purposes of this analysis, cases
are defined as any human intentional expo-
sure call managed by participating poison cen-
ters involving extended-release amphetamine
or extended-release oral methylphenidate.
Intentional exposures are used as surrogates
for abuse and misuse and are composed of
the following categories, which have standard-
ized definitions within the poison center data
collection system: suicide, intentional misuse,
abuse, intentional unknown, and withdrawal
cases.5 Cases are assigned to the reported 3-
digit ZIP code of the exposed individual’s res-
idence. A medical outcome category assess-
ing the effects of the exposure is assigned to
each case. Moderate effect medical outcomes
are defined as exposures in which “the pa-
tient exhibited symptoms as a result of the
exposure which are more pronounced, more
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prolonged or more of a systemic nature” but
not life-threatening or otherwise permanently
disabling, relative to minimally bothersome mi-
nor effects.5 Major effect medical outcomes are
defined as life-threatening effects or those lead-
ing to “significant residual disability or disfig-
urement.”5 More detailed descriptions of the
Poison Center Program have been published
elsewhere.9–11
RADARS System rates are calculated per
100,000 individuals and per 1,000 unique re-
cipients of a dispensed drug (URDD) in a 3-
digit ZIP code. Population and URDD values
for each program were assigned based on U.S.
Census data and reports from SDI, a healthcare
analytics firm (Plymouth Meeting, PA). The in-
terpretation of population rates per 100,000
individuals provides a measure of the abso-
lute burden on public health incurred from
the abuse, misuse, and diversion of the drug,
standardized for differences in population. The
URDD rate provides a drug-specific estimate of
unintended adverse consequences of the drug
based on the amount of the drug available in the
community. Each filling of a drug prescription in
a given quarter is counted as a single URDD, re-
gardless of the number of prescriptions received
during that time. The use of URDD to calcu-
late rates has been described elsewhere.12,13
Drug diversion and intentional exposure rates
per population and per URDD were calcu-
lated for extended-release amphetamines and
extended-release oral methylphenidate using
case counts from the Drug Diversion and Poison
Center Programs, respectively. Population and
URDD values are assigned to the 3-digit ZIP
codes in which the cases occurred. Rates are
plotted over time using the calculated rate cor-
responding to each calendar year quarter (quar-
ter 3 of 2007 to quarter 2 of 2011).
Graphs of rates over time were created, and
95% Poisson confidence limits were also calcu-
lated, along with mean rates (µ), for extended-
release oral methylphenidate and extended-
release amphetamines for both Drug Diversion
and Poison Center data using SAS Enterprise
Guide 4.2 (SAS Institute, Inc., Cary, NC). A sim-
ple linear regression model of the rate versus
time (allowing for autocorrelation via an AR[1]
error structure) is fit to the data. The slope of the
regression line indicates the expected increase
(if positive) or decrease (if negative) in rates per
year quarter. The trend models do not include
the 2 initial quarters of collected data to account
for potential effects of increasing prescription
rates following the introduction of a product to
market or the addition of a product to RADARS
System surveillance. These slopes, as well as
their corresponding p-values, are reported.
The protocols for data collection and analy-
sis in the RADARS System have been reviewed
by the institutional review boards governing
Nova Southeastern University (formerly Uni-
versity of Delaware) (RADARS System Drug
Diversion Program) and the Denver Health
and Hospital Authority (RADARS System Poison
Center Program). Arrest data reported through
the Drug Diversion Program are publicly avail-
able and are de-identified. In addition, all par-
ticipating poison centers obtained institutional






Beginning in quarter 3 of 2007, prescrip-
tions for extended-release amphetamines have
been trending steadily upward (2,460,411 in
quarter 3 of 2007 to 4,618,528 in quar-
ter 2 of 2011) (Figure 1). Over the same
time period, prescriptions for extended-release
oral methylphenidate increased only slightly
(2,957,314 in quarter 3 of 2007 to 3,291,121
in quarter 2 of 2011). Over the specified time-
frame, prescriptions for extended-release am-
phetamine increased 87.7%, whereas those
for extended-release oral methylphenidate
increased 11.3 %.
Drug Diversion
Drug Diversion population-based rates for
extended-release amphetamines ranged from
0.019 to 0.065 per 100,000 persons (µ = 0.038
per 100,000 persons) across the 16 quarters;
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aER amphetamine includes Adderall XR, Generic Adderall XR, Dexedrine Spansule, and Vyvanse. 


























































FIGURE 1. ADHD prescribing information for ER amphetaminea and ER oral methylphenidateb, IMS, Q3 of 2007 through Q2 of 2011.
URDD rates ranged from 0.028 to 0.062 per
1,000 URDD (µ = 0.042 per 1,000 URDD) (Ta-
ble 2). Drug Diversion population-based rates
for extended-release oral methylphenidate
ranged from 0.010 to 0.039 per 100,000 per-
sons (µ = 0.019 per 100,000 persons); URDD
rates ranged from 0.014 to 0.049 per 1,000
URDD (µ = 0.026 per 1,000 URDD) (Table 2).
Figure 2A shows Drug Diversion population
rates over time, while Figure 2B displays Drug
Diversion URDD rates over time.
Plotted over time, the estimated trend in
diversion population rates for extended-release
amphetamines shows a slight but significant in-
crease (slope = 0.0014, P = .043), whereas
no meaningful trends were observed in the es-
timated diversion URDD rates for extended-
release amphetamines (slope = –0.0003,
P = .563). The estimated trend in diver-
sion population rates for extended-release
oral methylphenidate shows a nonsignificant
increase over time (slope = 0.0005, P =
.459), as does the estimated trend in diver-
sion URDD rates for extended-release oral
methylphenidate (slope = 0.0006, P = .463).
The rates for the two formulations diverge no
more than 0.034 per 100,000 population or
per 1,000 URDD in any given quarter.
Poison Center Data
Poison Center intentional exposure rates per
population for extended-release amphetamines
ranged from 0.084 to 0.204 per 100,000 per-
sons (µ = 0.143 per 100,000 persons); URDD
rates ranged from 0.132 to 0.182 per 1,000
URDD (µ = 0.156 per 1,000 URDD) (Table 3).
Intentional exposure rates per population for
extended-release oral methylphenidate ranged
from 0.144 to 0.194 per 100,000 persons (µ =
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TABLE 2. RADARS System Drug Diversion Program: Total Extended-Release Amphetamine and Oral Methylphenidate Rates
Rate per Rate per 100,000
Quarter/Year 1,000 URDD 95% CI Population 95% CI
Total extended-release oral methylphenidate
Q3/2007 0.022 0.013–0.036 0.015 0.009–0.025
Q4/2007 0.016 0.009–0.029 0.012 0.007–0.022
Q1/2008 0.014 0.008–0.023 0.010 0.006–0.017
Q2/2008 0.024 0.016–0.037 0.016 0.011–0.025
Q3/2008 0.020 0.012–0.034 0.015 0.009–0.024
Q4/2008 0.020 0.012–0.033 0.016 0.010–0.027
Q1/2009 0.039 0.027–0.055 0.033 0.024–0.047
Q2/2009 0.037 0.026–0.053 0.024 0.017–0.035
Q3/2009 0.040 0.028–0.057 0.025 0.018–0.035
Q4/2009 0.018 0.010–0.031 0.014 0.008–0.024
Q1/2010 0.049 0.036–0.068 0.039 0.028–0.054
Q2/2010 0.015 0.008–0.026 0.010 0.005–0.017
Q3/2010 0.026 0.016–0.042 0.019 0.012–0.030
Q4/2010 0.015 0.008–0.028 0.012 0.007–0.022
Q1/2011 0.023 0.015–0.036 0.019 0.012–0.030
Q2/2011 0.045 0.031–0.064 0.031 0.022–0.044
Total extended-release Amphetamines
Q3/2007 0.035 0.023–0.052 0.022 0.015–0.033
Q4/2007 0.028 0.018–0.043 0.019 0.012–0.030
Q1/2008 0.048 0.036–0.063 0.034 0.026–0.045
Q2/2008 0.039 0.028–0.055 0.027 0.019–0.037
Q3/2008 0.049 0.036–0.067 0.038 0.028–0.052
Q4/2008 0.047 0.034–0.066 0.040 0.029–0.055
Q1/2009 0.048 0.035–0.065 0.042 0.031–0.057
Q2/2009 0.037 0.027–0.051 0.031 0.022–0.042
Q3/2009 0.042 0.031–0.057 0.034 0.025–0.046
Q4/2009 0.034 0.024–0.047 0.034 0.024–0.048
Q1/2010 0.062 0.048–0.079 0.065 0.051–0.084
Q2/2010 0.043 0.033–0.057 0.040 0.030–0.052
Q3/2010 0.037 0.026–0.051 0.038 0.027–0.052
Q4/2010 0.033 0.023–0.046 0.037 0.026–0.051
Q1/2011 0.043 0.032–0.056 0.051 0.039–0.067
Q2/2011 0.048 0.037–0.062 0.057 0.044–0.074
0.168 per 100,000 individuals); URDD rates
ranged from 0.197 to 0.254 per 1,000 URDD
(µ = 0.225 per 1,000 URDD) (Table 3). Fig-
ure 3A shows Poison Center intentional expo-
sure population rates over time, whereas Figure
3B displays Poison Center intentional exposure
URDD rates over time.
Plotted over time, the estimated trend
in intentional exposure population rates for
extended-release amphetamines shows a sig-
nificant increase (slope = 0.0073, P < .001);
similarly, the estimated trend in intentional ex-
posure URDD rates for extended-release am-
phetamines shows a significant increase over
time (slope = 0.0025, P = .007). The estimated
trend in intentional exposure population rates
for extended-release oral methylphenidate is
flat and shows a nonsignificant increase over
time (slope = 0.0004, P = .658), as does
the estimated trend in intentional expo-
sure URDD rates for extended-release oral
methylphenidate (slope = 0.0006, P = .585).
The greatest difference between extended-
release oral methylphenidate and extended-
release amphetamine rates per 100,000 indi-
viduals or per 1,000 URDD in any given quarter
was 0.098.
As shown in Figure 4, rates per 1,000
URDD for intentional exposure calls that re-
sulted in moderate or major medical out-
comes are generally slightly greater for, al-
though comparable with, extended-release oral
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FIGURE 2. RADARS System Drug Diversion Program: Total ER amphetamine and total ER oral methylphenidate rates per (a) 100,000
population and (b) per 1,000 URDD, all sites, Q3 of 2007 through Q2 of 2011.
methylphenidate than for extended-release
amphetamines. URDD rates for intentional
exposures resulting in moderate or major
medical outcomes for extended-release oral
methylphenidate ranged from 0.063 to 0.093
per 1,000 URDD (µ = 0.080 per 1,000
URDD), whereas those for extended-release
amphetamines ranged from 0.043 to 0.069
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TABLE 3. RADARS System Poison Center Program: Total Extended-Release Amphetamine and Oral Methylphenidate Rates
Rate per Rate per 100,000
Quarter/Year 1,000 URDD 95% CI Population 95% CI
Total extended-release oral methylphenidate:
Q3/2007 0.207 0.183–0.234 0.144 0.128–0.163
Q4/2007 0.225 0.201–0.251 0.170 0.152–0.190
Q1/2008 0.232 0.208–0.258 0.180 0.162–0.200
Q2/2008 0.236 0.212–0.263 0.168 0.151–0.188
Q3/2008 0.225 0.202–0.251 0.157 0.141–0.175
Q4/2008 0.236 0.214–0.260 0.187 0.170–0.207
Q1/2009 0.197 0.177–0.218 0.165 0.148–0.183
Q2/2009 0.228 0.205–0.253 0.160 0.144–0.178
Q3/2009 0.230 0.207–0.256 0.159 0.143–0.177
Q4/2009 0.207 0.186–0.231 0.154 0.138–0.171
Q1/2010 0.215 0.194–0.238 0.169 0.153–0.188
Q2/2010 0.231 0.208–0.256 0.169 0.152–0.187
Q3/2010 0.229 0.206–0.254 0.165 0.149–0.183
Q4/2010 0.211 0.190–0.234 0.166 0.150–0.185
Q1/2011 0.238 0.216–0.262 0.194 0.176–0.213
Q2/2011 0.254 0.230–0.282 0.173 0.156–0.192
Total extended-release Amphetamines:
Q3/2007 0.132 0.112–0.155 0.084 0.072–0.099
Q4/2007 0.143 0.124–0.165 0.101 0.088–0.117
Q1/2008 0.134 0.116–0.155 0.101 0.088–0.117
Q2/2008 0.141 0.123–0.162 0.105 0.091–0.120
Q3/2008 0.149 0.131–0.169 0.115 0.101–0.131
Q4/2008 0.154 0.137–0.174 0.129 0.114–0.145
Q1/2009 0.157 0.140–0.176 0.135 0.120–0.151
Q2/2009 0.166 0.149–0.185 0.150 0.134–0.167
Q3/2009 0.154 0.137–0.173 0.135 0.121–0.152
Q4/2009 0.161 0.144–0.179 0.158 0.142–0.175
Q1/2010 0.157 0.141–0.174 0.162 0.146–0.180
Q2/2010 0.182 0.165–0.201 0.181 0.164–0.200
Q3/2010 0.141 0.126–0.158 0.141 0.126–0.158
Q4/2010 0.182 0.166–0.201 0.197 0.179–0.216
Q1/2011 0.160 0.145–0.177 0.187 0.169–0.206
Q2/2011 0.181 0.165–0.199 0.204 0.186–0.224
per 1,000 URDD (µ = 0.058 per 1,000
URDD). Plotted over time, the estimated trends
in URDD rates for both extended-release
amphetamines (slope = 0.0013, P = .017)
and extended-release oral methylphenidate
(slope = 0.0013, P = .019) are nearly paral-
lel and increasing significantly.
DISCUSSION
Our findings suggest that the risk for non-
medical use and diversion is similar between
extended-release amphetamine and extended-
release oral methylphenidate. By using U.S.
poison center data that distinguish extended-
release amphetamine and extended-release
oral methylphenidate and analyzing data in
the context of availability of drug, our research
builds on earlier studies that examined prescrip-
tion stimulant exposures.14,15 Similarly, our re-
search is a useful context for previously pub-
lished studies reporting survey-based data on
the proportion of prescription stimulant abuse
attributed to immediate- and extended-release
formulations; these previous studies were not
designed to investigate specific formulations of
stimulants or the relationship with availability
based on prescriptions.16,17
Prescriptions for both extended-release for-
mulations have increased over time, albeit at a
faster rate for extended-release amphetamine.
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FIGURE 3. RADARS System Poison Center Program: Total ER amphetamine and total ER oral methylphenidate rates per (a) 100,000
population and (b) per 1,000 URDD, all sites, Q3 of 2007 through Q2 of 2011.
Concurrently, availability adjusted rates of non-
medical use and diversion for both extended-
release amphetamine and extended-release
oral methylphenidate have remained compar-
atively level over the past 4 years relative to
population and available drug. In the Drug Di-
version study, the estimated population trend
for extended-release amphetamine shows a






































Total ER Oral Methylphenidate
ER AMP:  slope=0.0013, p-value=0.017
ER Oral MPH:  slope=0.0013, p-value=0.019
FIGURE 4. Total ER amphetamines and total ER oral methylphenidate rates per 1,000 URDD, moderate and major medical outcomes
associated with intentional exposures, Q3 of 2007 through Q2 of 2011.
mildly significant increase over time, but when
taking product availability into account (see
URDD rate), no meaningful trends are ap-
parent. In the Poison Center study, the esti-
mated population and URDD trend rates for
extended-release amphetamine show a signifi-
cant increase over time. However, when taking
product availability into account, URDD trend
rates for extended-release amphetamines are
below extended-release oral methylphenidate
throughout the timeframe presented. Given
the overall low rates, the narrow differences
between extended-release amphetamine and
extended-release oral methylphenidate are not
clinically meaningful. For example, although
there has been general growth in nonmedi-
cal use and diversion of prescription stimu-
lants, rates are much lower than for opioids,
which vary within the class, based on previ-
ous research with the same data sources (i.e.,
the RADARS Drug Diversion and Poison Center
Programs).10,12
The growth in prescriptions is not surpris-
ing given the increased diagnosis of ADHD
among children and adults, resulting in an ex-
pansion of the indicated patient population for
ADHD prescription stimulants. Parent-reported
ADHD lifetime diagnosis of 4–17 year olds
increased from 7.8% to 9.5% between 2003
and 2007.18 Based on a nationally represen-
tative survey conducted from 2001 to 2003
that determined ADHD using diagnostic cri-
teria, prevalence among adults has been esti-
mated at 4.4%.19
Two rates are presented in the current ar-
ticle that should be considered simultaneously.
The interpretation of the population rate (e.g.,
cases per 100,000 individuals) is the absolute
burden on public health incurred from the
abuse, misuse, and diversion of the drug. The
interpretation of the URDD rate is the drug-
specific unintended adverse consequences of
medical availability, accounting for the amount
of drug in outpatient medical use. Both rates
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must be used in tandem to achieve a full pic-
ture of the public health consequences.
Similarly, law enforcement and health out-
comes can be used simultaneously because to-
gether they provide perspective on the effect of
nonmedical use of ADHD stimulants on pub-
lic health, are useful to inform policy decisions
about interventions, and support decision mak-
ing by law enforcement about resource alloca-
tion. The RADARS System Drug Diversion and
Poison Center Programs provide an opportu-
nity to explore nonmedical stimulant use across
law enforcement and health settings. Although
there is a broader debate about the balance be-
tween a health-oriented and punitive approach
to drug policy interventions, we suggest that
both indicators should be examined jointly to
derive a broader understanding of the unin-
tended consequences of prescription stimulant
availability.
Our results show that there is misuse, abuse,
and diversion of extended-release prescription
stimulants that cannot be ignored. However,
the rates are low, with little difference in rates
between extended-release amphetamine and
extended-release methylphenidate. Continuing
to monitor these rates over time will provide
important information on the public health ef-
fect of these products and guide the initiation
of mitigation strategies to address their misuse,
abuse, and diversion.
Limitations
Study limitations extending from two types of
potential confounding are inherent to the data
sources available. First, individuals exposed
to extended-release oral methylphenidate may
be inherently different from those exposed to
extended-release amphetamines, making com-
parisons between the two populations difficult
(also known as confounding by indication or
channeling).20 In the case of comparing two
controlled substances for similar indications, if
one drug is perceived to have lower abuse li-
ability (historically, scientifically, or by word-
of-mouth), clinicians may prescribe that drug
preferentially to high-risk patients, who would
be more likely to abuse it than a population
where abuse risk was more heterogeneously
distributed, and patients and the general
population may similarly be more likely to
use it nonmedically.i It would be a useful
follow-up study to compare use and abuse
risk patterns among patients prescribed the two
medications. The second type of potential con-
founding arises from the lack of control of ex-
ternal factors that may influence the observed
changes in abuse and diversion rates over time.
Observational time-series analyses may be sub-
ject to influences not measured in this study.
Cases in the Drug Diversion Program may
represent a broad range of law enforcement
events; one case may represent a single pill or a
pharmacy robbery involving hundreds or thou-
sands of pills. Law enforcement reporting is also
subject to available resources within reporting
jurisdictions and the prioritization of prescrip-
tion drug diversion investigations. Furthermore,
national coverage for the Drug Diversion Pro-
gram is influenced by both the number of in-
formants who report during any given quarter,
which varies over time, and slight variations in
covered jurisdictions, which results in 3-digit
ZIP code coverage fluctuations.
Poison centers are spontaneous reporting
systems, which gives rise to problems of un-
derstanding how complete a representation of
all exposure cases was observed. It is unclear
whether the variations observed in this study
can be accounted for by known causes for
changes in poison center use.21,22 However, in
such scenarios, poison center use would have
to have led to differential reporting between
the drugs to affect changes in the conclusion.
Inclusion of only RADARS System poison cen-
ters affects the generalizability of our findings.
However, the 45 states (as of quarter 2 of 2011)
represented in this analysis include some of the
largest metropolitan areas in the country, as well
as states with a considerable rural population.
Collectively, cases could have arisen from ap-
proximately 85.9% of the U.S. population cov-
ered by the poison centers in this analysis. Al-
though site selection was originally directed to
include states with substantial rural areas, we
believe that the final sample included a reason-
able mix of metropolitan and non-metropolitan
areas.
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Statistical testing was conducted to iden-
tify the presence of linear trending in the ob-
served phenomena. The appropriateness of the
assumption of a linear effect over time (even
accounting for autocorrelation) can be ques-
tioned. However, our previous experience with
poison center and drug diversion data suggest
that this is an appropriate assumption for other
pharmaceutical controlled substances at this
stage of market maturity.3,7 When rates over
time were inspected empirically (Figures 2 and
3), linear trend was a natural choice for testing.
This study focused on the rates of non-
medical use and diversion of extended-
release amphetamine and extended-release
oral methylphenidate in the United States be-
cause these products are commonly prescribed
in the United States and because of interest
in extended-release formulations as a possi-
ble mechanism to improve adherence among
patients. The data show that the nonmedical
use and diversion of prescription extended-
release amphetamine and extended-release
oral methylphenidate are low and similar; how-
ever, our analysis did not disaggregate the indi-
vidual contributory effects of particular formula-
tions on the observed chemical substance level
effects. Conducting a similar analysis of specific
products within each drug class might be of fu-
ture interest.
Note
i. The prescribing information for all prescription stim-
ulants for the treatment of ADHD have a black box
warning about misuse, abuse, and dependence.
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